Overview
Focused oncology panels delivering rapid and cost-effective molecular profiling.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● Defined clinical indication ● Cost-sensitive testing
Applicable Cancer Types
Solid tumors, Hereditary cancers, Lung cancer
What is Covered?
- Pan Cancer 86 genes
- Hotspot panel
- Hereditary Oncology 47 genes
- Lung Fusion panel
Clinical Utility
- Treatment selection
- Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
Targeted high-depth NGSkey Features
| Parameter | Details |
|---|---|
|
Sample Type |
FFPE/Blood |
|
Samples |
1 FFPE block or 10–15 slides |
|
Turnaround Time |
10–14 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |